Jin‐Yuan Shih

机构：National Taiwan University Hospital · ORCID：0000-0002-2854-5067

发表论文 479 篇 · 总被引 18588 次 · h-index 65

代表论文

• Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer (2025 · Journal of Clinical Oncology · 被引 76)
• Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial (2025 · Journal of Thoracic Oncology · 被引 35)
• First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). (2025 · Journal of Clinical Oncology · 被引 10)
• Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. (2025 · Journal of Clinical Oncology · 被引 3)
• Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial. (2025 · Journal of Clinical Oncology · 被引 3)
• PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC (2025 · Journal of Biomedical Science · 被引 2)